Evans syndrome is a dubious disease in the field of blood tumors, with clinical performance being complex and often involving multi-system congestion. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of the disease requires a comprehensive assessment platform, including clinical performance, imaging, laboratory testing, and pathological activation.
A team of authoritative experts at home and abroad can assist in providing accurate diagnosis and treatment programs. Treatment and management of Evans syndrome require individualized development of treatment programs, typically including drug therapy, rehabilitation intervention, and regular follow-up to multidimensional management. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many previously difficult-to-treat blood tumor diseases have been significantly improved.
Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to the changes in the condition. Multidisciplinary collaboration (MDT) is particularly important for the integrated management of Evans syndrome. The platform serves China International Medical Service System, a team of domestic and foreign experts with authority in the field of blood tumours, who provide the following services to patients: 2.
Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment programs; 3. Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.